p53 and H‐ras Mutations and Microsatellite Instability in Renal Pelvic Carcinomas of NON/Shi Mice Treated with N‐Butyl‐N‐(4‐hydroxybutyl)‐nitrosamine: Different Genetic Alteration from Urinary Bladder Carcinoma

We previously reported p53 mutations to be frequent (greater than 70%), whereas both H‐ras mutations and microsatellite instability (MSI) were infrequent (about 10%), in urinary bladder carcinomas (UBCs) and their metastatic foci in the N‐butyl‐N‐(4‐hydroxybutyl)nitrosamine (BBN)‐induced mouse urothelial carcinogenesis model. In the present study, an analysis of p53 and H‐ras mutations as well as MSI was performed on 12 renal pelvic carcinomas (RPCs) and 8 metastatic or invading foci produced by the same experimental procedure. Histologically, 10 of the RPCs were transitional cell carcinomas and the remaining 2 were squamous cell carcinomas. p53 mutations were infrequent and only found in one primary RFC (8%), its metastatic foci and an invading lesion in another animal (in a total 2 of 12; 17%). H‐ras mutations were slightly more frequent (found in 3 of 12 animals; 25%), 4 of 5 involving codon 44, GTG to GCG, not a hot‐spot reported for human cancers. In two cases, H‐ras mutations were confined to lung metastasis and not detectable in their primary RPCs. MSI analysis was available for 6 pairs of primary RPCs and their metastatic foci, and 4 animals (67%) had MSI at one or more microsatellite loci. Overall, the distribution of genetic alterations differed from that in UBCs produced by the same experimental protocol. The results thus suggest that different genetic pathways may participate in carcinogenesis of the upper and lower urinary tract due to BBN.